Abstract 1143P
Background
1L ICI combination therapy has transformed the tx paradigm for non-oncogene-addicted NSCLC. Acquired resistance to ICI therapy could be influenced and reversed by the use of subsequent anti-angiogenic therapy. In this setting, non-interventional data may help to guide post-progression therapeutic decision making. We therefore examined tx outcomes with 2L NIN + DOC with respect to response to 1L ICI combination therapy, and performance status (ECOG PS) at baseline.
Methods
In this analysis of Cohort C of the ongoing, non-interventional VARGADO study (NCT02392455), eligible pts had locally advanced, metastatic or locally recurrent adenocarcinoma NSCLC and received 2L NIN + DOC in routine clinical practice after failure on 1L ICI combined with chemotherapy. The primary endpoint is 1-year survival rate (not yet mature). Tumour response was according to investigator review.
Results
In 176 pts enrolled in Cohort C, median age was 63 years (range: 37–84), 106 pts (60.2%) were men, 138 pts (78.4%) had an ECOG PS 0–1, and 157 pts (89.2%) had received prior 1L pembrolizumab-based combination therapy. In the overall population, objective response rate and disease control rate with 2L NIN + DOC were 35.0% (42/120 pts) and 68.3% (82/120 pts), respectively. Median PFS was 4.8 months (95% CI: 3.5–5.3) and no clear differences were seen with respect to best response to 1L therapy. Median OS was 8.1 months (95% CI: 6.3–11.2) in the overall population. There was a possible association between OS benefit with 2L tx and partial response (PR) as best response to 1L therapy (median OS 9.1 months [95% CI: 5.4–18.3]) especially in those pts with ECOG PS 0–1 (median OS 11.2 months [95% CI: 5.2–21.0]).
Conclusions
Our results support 2L NIN + DOC as an effective tx option in pts with advanced adenocarcinoma NSCLC following 1L ICI combination therapy. Best response to 1L tx and ECOG PS may be valuable surrogate markers associated with clinical benefit of 2L NIN + DOC. These findings warrant further evaluation of the effect of these parameters on 2L tx outcomes after 1L ICI combination therapy.
Clinical trial identification
NCT02392455.
Editorial acknowledgement
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Jim Sinclair, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by Boehringer Ingelheim.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
C. Grohé: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim; Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim; Financial Interests, Personal, Other: Boehringer Ingelheim. T.C. Wehler: Financial Interests, Personal, Advisory Role: Boehringer Ingelheim, Pfizer, Roche, MSD, BMS, Takeda, Janssen, AstraZeneca; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim, Pfizer, Roche, MSD, BMS, Takeda, Janssen, AstraZeneca; Financial Interests, Personal, Other, Financing of Scientific Investigations: Boehringer Ingelheim, AstraZeneca; Financial Interests, Personal, Other, travel expenses: Boehringer Ingelheim, AstraZeneca, Pfizer, Janssen. S. Henschke: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Merck Sharp & Dohme, Roche; Financial Interests, Personal, Stocks/Shares: Health care ETF, Thermo Fisher Scientific below 5000€; Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Merck Sharp & Dohme, Roche; Financial Interests, Personal, Other, Honoraria: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Merck Sharp & Dohme, Roche; Financial Interests, Personal, Other, Financing of Scientific Investigations: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Merck Sharp & Dohme, Roche; Non-Financial Interests, Institutional, Other, Provision of study data as part of the VARGADO study and review of the manuscript (no payment): Provision of study data as part of the VARGADO study and review of the manuscript (no payment); Financial Interests, Personal, Other, Travel: Amgen, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Chugai, Merck Sharp & Dohme, Roche; Financial Interests, Personal, Invited Speaker, Equipment, materials, drugs, medical writing, gifts or other services: Boehringer Ingelheim (in the context of participation in the VARGADO study). I. Dittrich: Financial Interests, Personal, Advisory Role: Boehringer Ingelheim GmbH, Pfizer GmbH, BMS GmbH & Co. KG, AstraZeneca GmbH. S. Hammerschmidt: Financial Interests, Personal, Advisory Role: Boehringer Ingelheim; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim. C. Schiefer: Financial Interests, Personal, Speaker’s Bureau: Chiesi, Boehringer Ingelheim, GSK, AstraZeneca; Financial Interests, Personal, Advisory Board: Chiesi, Boehringer Ingelheim, GSK; Financial Interests, Personal, Stocks/Shares: Fresenius; Financial Interests, Institutional, Product Samples: Chiesi, AstraZeneca, GSK; Financial Interests, Institutional, Training: Chiesi, AstraZeneca; Financial Interests, Personal, Other, Honoraria: Chiesi, Boehringer Ingelheim, GSK, AstraZeneca; Financial Interests, Personal, Other, Financing of Scientific Investigations: Chiesi, Boehringer Ingelheim, GSK, AstraZeneca. E. von der Heyde: Financial Interests, Personal, Full or part-time Employment, Fulltime Partner in the oncological practice at Raschplatz, Hanover: Raschplatz, Hanover; Financial Interests, Personal, Principal Investigator: BMS, Boehringer Ingelheim, Novartis, AstraZeneca, Ipsen, Pierre Fabre; Financial Interests, Personal, Advisory Role: BMS, Boehringer Ingelheim, Novartis, AstraZeneca, Ipsen, Pierre Fabre; Financial Interests, Personal, Other, Honoraria - Consulting fees: BMS, Boehringer Ingelheim, Novartis, AstraZeneca, Ipsen, Pierre Fabre; Financial Interests, Personal, Funding, Expenses for non-interventional Studies: Boehringer Ingelheim, Novartis, BMS, Ipsen. W. Schuette: Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, MSD, Roche, Novartis, GSK, Sanofi; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, MSD, Roche, Novartis, GSK, Sanofi; Non-Financial Interests, Institutional, Principal Investigator: Boehringer Ingelheim, MSD, Novartis, Roche, GSK, AbbVie, AstraZeneca, Mirati; Financial Interests, Personal, Other, Honoraria: Boehringer Ingelheim, MSD, Novartis, Roche, GSK, Sanofi. J. Atz: Financial Interests, Personal, Full or part-time Employment: Boehringer Ingelheim. R. Kaiser: Financial Interests, Personal, Full or part-time Employment: Boehringer Ingelheim. All other authors have declared no conflicts of interest.